309 related articles for article (PubMed ID: 16637572)
1. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
3. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
4. Problems in the classification of CMML--dysplastic versus proliferative type.
Germing U; Gattermann N; Minning H; Heyll A; Aul C
Leuk Res; 1998 Oct; 22(10):871-8. PubMed ID: 9766745
[TBL] [Abstract][Full Text] [Related]
5. Chronic myelomonocytic leukemia: lost in classification?
Bowen DT
Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.
Occhipinti E; Correa H; Yu L; Craver R
Pediatr Blood Cancer; 2005 Mar; 44(3):240-4. PubMed ID: 15368549
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
9. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
10. [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].
Germing U; Strupp C; Meckenstock G; Giagounidis A; Minning H; Aul C
Med Klin (Munich); 1999 Sep; 94(9):467-72. PubMed ID: 10544608
[TBL] [Abstract][Full Text] [Related]
11. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
12. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases.
Hasle H; Niemeyer CM; Chessells JM; Baumann I; Bennett JM; Kerndrup G; Head DR
Leukemia; 2003 Feb; 17(2):277-82. PubMed ID: 12592323
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?
Voglová J; Chrobák L; Neuwirtová R; Malasková V; Straka L
Leuk Res; 2001 Jun; 25(6):493-9. PubMed ID: 11337023
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplasia and myeloproliferative disorders in children.
McKenna RW
Am J Clin Pathol; 2004 Dec; 122 Suppl():S58-69. PubMed ID: 15690643
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
17. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
18. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
Loghavi S; Wang SA
Surg Pathol Clin; 2019 Sep; 12(3):651-669. PubMed ID: 31352979
[TBL] [Abstract][Full Text] [Related]
19. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
Ragon BK; Savona MR
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S37-S42. PubMed ID: 28760301
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
Loghavi S; Sui D; Wei P; Garcia-Manero G; Pierce S; Routbort MJ; Jabbour EJ; Pemmaraju N; Kanagal-Shamanna R; Gur HD; Hu S; Zuo Z; Medeiros LJ; Kantarjian HM; Khoury JD
Blood Adv; 2018 Aug; 2(15):1807-1816. PubMed ID: 30054307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
